

## 2017 Beyond Fundamentals of Hematopoietic Cell Transplantation (HCT) Training Course

Held in Conjunction with the  
2017 BMT Tandem Meetings  
February 22 - February 23, 2016  
Gaylord Palms Resort & Convention Center  
Orlando, FL

---

For more information about the 2017 Beyond Fundamentals of Hematopoietic Cell Transplantation (HCT) Training Course, visit <http://www.cvent.com/d/wvqkc1>. No brochures will be mailed this year.

### Pharmacist Continuing Education Information



Syntaxx Communications, Inc. is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Syntaxx Communications has assigned **16.00** contact hours (**1.60 CEUs**) of continuing pharmacy education credit for this knowledge- and application-based activity. This 2-day conference will incorporate **22** individual activity sessions that combined will fulfill the **16.00 hours** of CE. The target audience for this accredited activity is pharmacists.

To receive continuing pharmacy education credit for the conference, participants must attend the sessions in their entirety and complete the associated program evaluation forms. Additionally, all US-based pharmacists must supply their National Association of Boards of Pharmacy (NABP) electronic Profile Identification (ePID) number and their birth month and day (MM/DD). No credit can or will be issued without this information. To acquire an NABP ePID, go to <http://www.nabp.net> and click on CPE Monitor.

### Faculty and Agenda

The full list of faculty and 2-day agenda are provided below.

### Published

February 22, 2016 – February 23, 2019

### Universal Activity Numbers

0299-9999-17-014-L01-P – 0299-9999-17-035-L01-P

This 2-day conference will be comprised of 22 individual sessions identified by 22 distinct UAN numbers.

### Overall Conference Educational Objectives

After attending the 2017 Beyond Fundamentals of HCT Training Course, participants should be able to:

1. Describe the advantages and disadvantages of available strategies for stem cell mobilization.
2. Analyze the pharmacologic properties and expected toxicity profiles of medications commonly used in HCT preparative regimens.
3. Describe current challenges in managing nausea and vomiting in patients undergoing HCT; outline appropriate monitoring, prevention, and treatment strategies for these patients.
4. Assess patient eligibility criteria for HCT based on disease-specific transplantation outcomes.

5. Describe strategies available for disease control after HCT.
6. Explain interventions to prevent and treat mucositis and maintain nutritional status before and after HCT.
7. Define sinusoidal obstructive syndrome (SOS) and associated risk factors; outline prevention and treatment strategies for SOS.
8. Summarize common bacterial pathogens and unique approaches to prophylaxis and treatment in patients undergoing HCT.
9. Outline the incidence of invasive fungal infections in HCT patients and describe strategies for prophylaxis, empiric therapy, and treatment of documented fungal infections.
10. Develop a prophylactic and treatment strategy for common viral infections in HCT patients.
11. Evaluate risk factors, prevention strategies, pharmacologic treatment, monitoring guidelines, and supportive care strategies for acute graft-versus-host disease (GVHD).
12. Distinguish risk factors, pathophysiology, prevention and treatment strategies, and long-term complications between acute and chronic GVHD.
13. Identify and develop a treatment strategy for common pulmonary complications associated with HCT.
14. List long-term complications and survivorship challenges experienced by patients undergoing HCT.
15. Describe how population pharmacokinetic models are used to support busulfan therapeutic drug monitoring and achievement of desired outcomes in HCT patients receiving busulfan.
16. Recognize risk factors, newer diagnostic criteria, and appropriate treatment strategies associated with transplant-associated thrombotic microangiopathy (TA-TMA).
17. Outline prevention and treatment strategies for acute and chronic neurologic toxicities caused by either preparative regimens or infectious complications in HCT patients.
18. Explain the impact of immune reconstitution on HCT-related outcomes.
19. Identify key physiologic changes, risk factors, and benefits that support the need for revaccination in patients who have undergone HCT; formulate a vaccination schedule for a post-HCT patient.
20. Evaluate differences in transplant indications and preparative regimen pharmacokinetics and pharmacodynamics when comparing pediatric and adult HCT populations.

## Program Evaluation Forms

The program evaluation forms may be accessed and completed online. These forms will be sent to attendees via a link provided by the National Marrow Donor Program. All participants completing program evaluation forms will receive a certificate of attendance provided by the National Marrow Donor Program.

For problems or issues related to continuing pharmacy education, please contact Amber Lawson at Syntaxx Communications:

E-mail: [alawson@syntaxxcomm.com](mailto:alawson@syntaxxcomm.com)

Phone: 859.940.8201

Mail: 305 W Country Dr, Johns Creek, GA 30097

## **Fees**

Early registration fees until October 3, 2016 are \$425 per person and registration fees after the early registration deadline of October 3, 2016 are \$475 per person. No additional fee for the 2-day (February 22, 2016 – February 23, 2017) Beyond Fundamentals of HCT Training Course will be charged to attendees requesting continuing pharmacy education (CPE) credit.

## **Required Computer Hardware/Software**

Educational materials and handouts will be posted on the ASBMT website and available for registrants to print before the activities of this 2-day conference commence. Registrants are encouraged to print the materials before arriving at the conference. Printers will not be available onsite for conference attendee use. A business center will be available to those willing to pay for copies.

Registrants will need an Internet connection in order to use the mobile application for the ARS/live polling portions of the program or the website (using electronic devices, such as a PC, Mac, tablet, or smart phone). Please note that PC and Apple computers do not support the Bravura Technologies Mobile Application that will be used for the ARS/live polling portion of each activity. The application to search and download for an IOS/Android tablet/mobile phone is BMTTANDEM (Bravura Technologies).

## **Financial Support**

TBD

## **Financial Disclosures**

TBD

There are no known conflicts of interest at this time; investigational/off-label use of drugs may be discussed.

# Beyond Fundamentals of HCT Training Course Agenda

## DAY 1 - Wednesday, February 22, 2017

Session Start / End Time	Session Length	Session Title
8:00 am - 8:15 am	15 mins	Welcome and Opening Remarks
8:15 am - 9:15 am	60 mins	Indications for HCT
9:15 am - 10:15 am	60 mins	Preparative Regimens
10:15 am - 10:30 am	15 mins	Morning Break
10:30 am - 11:00 am	30 mins	Busulfan PK Review
11:00 am - 11:30 am	30 mins	Sinusoidal Obstructive Syndrome
11:30 am - 12:00 pm	30 mins	Mucositis
12:00 pm - 12:30 pm	30 mins	Antiemetics
12:30 pm - 1:15 pm	45 mins	Lunch
1:15 pm - 1:45 pm	30 mins	Mobilization
1:45 pm - 2:45 pm	60 mins	Infection - Antibacterial
2:45 pm - 3:00 pm	15 mins	Afternoon Break
3:00 pm - 4:00 pm	60 mins	Infection - Viral
4:00 pm - 5:00 pm	60 mins	Infection - Antifungal
5:00 pm - 5:30 pm	30 mins	Infections Panel Discussion

## DAY 2 - Thursday, February 23, 2017

Session Start / End Time	Session Length	Session Title
8:00 am - 9:00 am	60 mins	Acute GVHD
9:00 am - 10:00 am	60 mins	Chronic GVHD
10:00 am - 10:30 am	30 mins	GVHD Panel Discussion
10:30 am - 10:45am	15 mins	Morning Break
10:45 am- 11:15 am	30 mins	Transplant-Associated Thrombotic Microangiopathy
11:15 am - 11:45 am	30 mins	Neurologic Complications
11:45 am - 12:15 pm	30 mins	Pulmonary Complications
12:15 pm - 1:00 pm	45 mins	Lunch
1:00 pm - 2:00 pm	60 mins	Pediatrics – Specific Considerations
2:00 pm - 3:00 pm	60 mins	Immune Reconstitution
3:00 pm - 3:15 pm	15 mins	Afternoon Break
3:15 pm - 4:15 pm	60 mins	Post-HCT Strategies
4:15 pm - 4:45 pm	30 mins	Vaccinations
4:45 pm - 5:15 pm	30 mins	Long-Term Complications
5:15 pm - 5:30 pm	15 mins	Closing Remarks/Program Evaluation

GVHD, graft-versus-host disease; HCT, hematopoietic cell transplantation; PK, pharmacokinetics.